[go: up one dir, main page]

WO1999030683A1 - Preparation a temps de sejour prolonge dans la zone d'application - Google Patents

Preparation a temps de sejour prolonge dans la zone d'application Download PDF

Info

Publication number
WO1999030683A1
WO1999030683A1 PCT/DE1998/003739 DE9803739W WO9930683A1 WO 1999030683 A1 WO1999030683 A1 WO 1999030683A1 DE 9803739 W DE9803739 W DE 9803739W WO 9930683 A1 WO9930683 A1 WO 9930683A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation according
active ingredient
preparation
particles
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1998/003739
Other languages
German (de)
English (en)
Inventor
Roland Bodmeier
Philippe Maincent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU24101/99A priority Critical patent/AU2410199A/en
Priority to EP98966561A priority patent/EP1037606A1/fr
Publication of WO1999030683A1 publication Critical patent/WO1999030683A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • This invention describes solid, rapidly disintegrating preparations to ⁇ that the eye, extend the residence time at the site of action, for example.
  • Too short a residence time of the active ingredient at the application site is a common problem when using medicinal forms on mucous membranes, particularly in the case of ophthalmic forms, but also in the case of vaginal, rectal or nasal preparations.
  • the most commonly used ophthalmic drug forms are drug drops. Eye drops have several disadvantages. Most of the drops are immediately washed out of the eye or only partially attached to the eye due to incorrect application technology. To prolong the dwell time and thus the pharmacological effect, liquid systems have been developed that increase their viscosity in contact with the tear fluid through gelation. These liquid preparations contain polymers which gel either by pH or temperature change (US 5,192,535, US 5,077,033).
  • the preparations according to the invention are solid preparations which, after application, e.g. on the eye, quickly disintegrate and increase the length of stay.
  • the present invention relates to a solid preparation which rapidly disintegrates in water and which extends the residence time of the active ingredient at the application site.
  • the active substance is a pharmacologically active substance. It is preferred that the active ingredient is enclosed in particles. It is further preferred that the active ingredient is enclosed in pellets.
  • the active ingredient is enclosed in microparticles. It is in turn preferred that the active ingredient be enclosed in particles with a particle size predominantly smaller than 20 ⁇ m.
  • the active ingredient is enclosed in colloidal particles. It is also preferred that the active ingredient be enclosed in liposomes. It is also preferred according to the invention that the active substance is enclosed in nanoparticles.
  • the preparations according to the invention are further characterized in that the carrier material of the particles is a polymer. It is preferred here that the Tragermateri ⁇ al of the particles, a cellulose derivative (eg Ethylcellulo- se, acetate phthalate cellulose acetate, cellulose acetate butyrate, cellulose, Hydroxypropylmethylphthalat) or an acrylate derivative (for example, poly (methyl methacrylate), Eudragits, cyanoacrylates) is.
  • a cellulose derivative eg Ethylcellulo- se, acetate phthalate cellulose acetate, cellulose acetate butyrate, cellulose, Hydroxypropylmethylphthalat
  • an acrylate derivative for example, poly (methyl methacrylate), Eudragits, cyanoacrylates
  • the carrier material of the particles is a biodegradable polymer from the group of polyanhydrides, polyesters (eg polylactide glycolides), polyorthoesters or polyacetals). It is particularly preferred that the carrier material of the particles is a lipid.
  • the particles preferably also have bioadhasive properties.
  • the active ingredient is bound to an ion exchange resin.
  • the preparation according to the invention releases the active ingredient with a delay. According to the invention, they can also release the active ingredient more quickly.
  • the preparations according to the invention also improve the stability of the active ingredient. According to the invention, the irritation or the irritation effect of the active ingredient is reduced.
  • the preparation also contains bioadhasive substances. It is preferred here that the bioadhasive substances are polymers.
  • Preparations according to the invention which contain polyacrylic acid, sodium algate, chitosan, methylethyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, gellan gum, lectins or their mixtures or derivatives are particularly preferred.
  • Another object of the present invention is a method for producing a preparation according to the invention.
  • the preparation is prepared by lyophilization.
  • the active ingredient or active ingredient-containing particles are / are incorporated into a liquid phase and the liquid preparation is introduced into a mold and lyophilized.
  • the preparation is produced by extrusion.
  • the preparation is produced by pressing.
  • a method is also in accordance with the invention, in which particles containing the active substance are incorporated into the preparation.
  • proteins eg gelatin, albumins, etc.
  • polysaccharides eg starch, agar-agar, carrageenan, tragacanth, dextran, dextrin, chitosan, alginates, gum arabic, pectin, xanthan gum, gellan
  • cellulose derivatives methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose
  • vinyl derivatives polyvinyl alcohol, polyvinyl pyrrolidone, etc.
  • the present invention also relates to tablet- or pellet-like or film-like or rod-like preparations which contain a preparation according to the invention. According to the invention, preference is given to using the preparations according to the invention on the eye.
  • Another object of the present invention is a device for applying a preparation according to the invention at the application site.
  • the preparations according to the invention are solid, rapidly disintegrating preparations which are used on the eye, vaginally, rectally or nasally and which prolong the residence time at the application site.
  • rapidly disintegrating is broad and does not only include, in the pure sense of the words, rapid disintegration, but means that the preparation quickly loses its original form after application, e.g. by complete or partial decay, swelling, or dissolution or dissolution or a combination of these processes. Ideally, the disintegration takes place within a few minutes.
  • a special aspect of the preparations according to the invention is an extension of the residence time of the
  • the solid preparations according to the invention form, for example, a viscous and / or bioadhasive mass, which extends the length of time of the active ingredient at the application site.
  • the active ingredient can be absorbed over a longer period of time or be locally effective.
  • Another advantage over normal inserts is that the preparation disintegrates quickly and is therefore not perceived as a foreign body for a long time.
  • the preparations according to the invention can be produced in various forms and by different methods known to the person skilled in the art for the respective application site. These processes include lyophilization, extrusion, pressing into moldings and the production of films.
  • the active ingredient or particles containing the active ingredient are mixed with a liquid carrier phase, this liquid phase is introduced into a mold (e.g. into the depressions of a blister pack), frozen and then lyophilized.
  • the shape and dimensions of the freeze-dried dosage forms are predetermined by the shape and dimensions of the containers. These dosage forms can either be further packaged directly in the containers or after removal from these containers.
  • the liquid preparations can also be appropriately lyophilized over a large area and the dosage forms of a specific format can then be produced from the freeze-dried areas by splitting, cutting and / or punching.
  • the porosity of the preparation can be influenced by the content of solvent or by dispersed gas.
  • the matrix obtained is porous and therefore allows rapid dissolution or rapid disintegration of the preparation. Preference is given to using water-soluble materials as carrier substances, since the fastest disintegration of the matrix can be brought about by placing the product in an aqueous medium.
  • Carrier materials can be proteins (e.g. gelatin, albumins, soybean proteins, etc.), polysaccharides (e.g. starch, agar-agar, carrageenan, tragacanth, dextran, dextrin, chitosan, alginates, pectins, gum arabic, xanthan gum, gellan gum etc.) ), Cellulose derivatives (methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose Hydroxyethyl cellulose, sodium carboxymethyl cellulose), methyl derivatives (polyvinyl alcohol, polyvinyl pyrrolidone, etc.) or mixtures of these carriers can be used.
  • proteins e.g. gelatin, albumins, soybean proteins, etc.
  • polysaccharides e.g. starch, agar-agar, carrageenan, tragacanth, dextran, dextrin, chitosan, alginates, pectins
  • Fillers such as sugar (eg lactose, glucose, mannitol, sorbitol, sucrose, etc.) can also be added.
  • the disintegration time depends on the composition, in particular on the type of carrier, its molar mass and its concentration.
  • the macromolecules can also be used in partially hydrolyzed form.
  • Rapidly disintegrating preparations are produced by pressing by methods known to those skilled in the art, such as direct tableting or pelletizing and subsequent compression. In addition to those listed under Lyophilization
  • Excipients and commonly used tableting excipients also excipients that are used in the rapidly disintegrating tablets intended for use in the oral cavity. In the case of vagal tablets in particular, it is also possible to use an effervescent mixture to accelerate the disintegration.
  • the shaping in films can be carried out by generally known methods such as, for example, spreading / knife coating or extrusion methods.
  • the division into single cans can be done by cutting, punching, embossing and comparable processes.
  • the polymers described above can correspondingly increase the residence time at the application site by a viscosity-increasing effect or, in some cases, additionally by a bioadhasive effect after the preparation rapidly disintegrates.
  • special bioadhasive substances can also be added to the preparation.
  • bioadhasive polymers that swell in contact with water are primarily used and demand the liability of the preparation at the application site.
  • the polymers include the polymers known to the person skilled in the art with bioadactive properties such as, for example, polyacrylic acid (Carbopol), sodium algmat, chitosan, methylethyl cellulose, sodium carboxymethyl cellulose, gellan gum, lectures etc. It is also possible to use polymers which, on the application site, are caused by pH, temperature or ions gel, increasing the viscosity of the preparation.
  • All drugs that are administered to the eye, nasally, vaginally or rectally can be used as active ingredients.
  • the active ingredients can act both locally and systemically. It is also possible to prepare solid, rapidly disintegrating preparations which contain polymers, e.g. Contain carboxymyl polymers (Carbopol) and, after dissolution, artificial tear fluids, e.g. to treat dry eyes.
  • a preparation according to the invention but free of pharmaceutical substances can also have a positive effect at the application site.
  • particles containing active ingredient is a special aspect of this invention.
  • the active ingredient is enclosed in m particles, for example polymeric microparticles, and is then incorporated into the preparation during manufacture.
  • Particulate drug carrier particles are mainly used to retard drug release.
  • the inclusion in the particles can, however, also lead to a reduced irritation at the application site, to an improved stability of the active substance, and, especially with colloidal particles, also to an acceleration of the active substance release (for example in the case of lipophilic active substances).
  • the term particle includes pellets (approx. 0.5 mm to 1.5 mm in diameter), microparticles and partial in the colloidal size range.
  • inclusion of the active ingredient in the particles is broad and includes, among other things, physical or chemical adsorption, coating the active ingredient and embedding it in the particles in dissolved or dispersed form
  • the active ingredient is made by various methods such as aqueous or organic phase separation, spray drying, solvent evaporation (solvent evaporation), melt solidification, melt emulsion formation, coating, etc. included.
  • the colloidal particles include liposomes and polymer or lipid nanoparticles.
  • the colloidal particles can be made by many methods known to those skilled in the art.
  • the carrier materials for the particles are the
  • Water-insoluble and water-soluble polymers of synthetic, semisynthetic and natural origin known to those skilled in the art and already listed above for example cellulose derivatives such as ethyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose sulfate phthalate, hydroxypropyl methyl phthalate, acrylates such as poly (methyl methacrylate), Eudragite, cyanoacrylate, Eudragite, Eudragite, eudragite, biudacrylite, Eudragite Degradable polymers such as polyanhydrides, polyesters (polylactide glycolides), polyorthoesters and polyacetal), and lipids (oils, fats, fatty acids, or waxes), and their derivatives or mixtures.
  • cellulose derivatives such as ethyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose sulfate phthalate, hydroxypropyl methyl phthalate,
  • Active ingredients can also be bound to ion exchange resins. This can lead to a delay in drug release or to a reduction in irritation.
  • the active substance bound to an ion exchange resin can in turn be enclosed in particles.
  • incorporating them into a solid preparation has many advantages compared to a liquid preparation.
  • the active ingredient diffuses substance during storage from the particles into the dispersion vehicle, retarding properties are lost.
  • undesired interactions between the solvent and the carrier material of the particles can occur in the liquid state, for example, this can lead to a change in the release profile during storage.
  • the stability of the active ingredient and the carrier polymers of the particles in the liquid phase is to be viewed much more critically; in the aqueous phase, for example, hydrolysis can occur. Furthermore, physical stability problems, for example sedimentation of the particles, are eliminated in the case of solid preparations.
  • ingredients in the preparations can be colorants, preservatives, buffer substances, substances to adjust the tonicity, plasticizers, etc.
  • Another advantage of solid compared to liquid preparations is that preservatives can be dispensed with if prepared accordingly.
  • biotechnologically manufactured active substances such as Peptides / proteins or oligonucleotides, penetration enhancers or enzyme inhibitors are added to the preparation. These auxiliary substances improve the absorption of the active substances.
  • the preparations according to the invention can be used in both human and veterinary medicine. If necessary, they can be sterilized or prepared aseptically. The preparations can be applied analogously to other solid pharmaceutical forms by the patient or the doctor, but also with special applicators known to the person skilled in the art.
  • Example 1 The invention is illustrated by the following examples, but should not be restricted thereby.
  • Example 1 The invention is illustrated by the following examples, but should not be restricted thereby.
  • the active ingredient / active ingredient-containing particles (0.1-20% by weight) are dissolved or dispersed in an aqueous gel solution (5-10% by weight) which has been autoclaved (121 ° C., 2 bar, 1 h).
  • the liquid phase is placed in a well of a blister pack, frozen and then freeze-dried.
  • a porous matrix is obtained which dissolves in water in a few minutes, sometimes within a few seconds.
  • Active ingredients active ingredient-containing particles:
  • Timolol maleate, Pilocarpm HCl and Betaxolol HCl in dissolved form were used as active ingredients.
  • Pilocarpm base was precipitated by increasing the pH and dispersed in the aqueous solution e.
  • Betaxolol was also bound to an ion exchange resin (Amberlite IRP-69) and then dispersed in the aqueous solution.
  • Polycaprolactone, ethyl cellulose or polylactide glycolide - nano or micro particles produced by spray drying or solvent evaporation process, in the case of nanoparticles by subsequent homogenization
  • lipid nano or micro particles produced by melt emulsion processes or spray solidification
  • starch In addition to or instead of the gelatin, starch, sodium alginate, hydroxypropylmethyl cellulose, gellan gum, polyalcohol and polyvinylpyrrolidone were used as carrier material for the porous matrix. Mannitol was used as an additional filler. Polyacrylic acid, carbopol (0.1-0.5%) or sodium carboxymethyl cellulose were added to the aqueous phase as bioadhasive polymers before the lyophilization.
  • the dwell time at the Kanmchen eye could e.g. with indium DTPA-labeled gelatin inserts (without special bioadhasive polymers) to 62 mm compared to 10 mm, achieved with an aqueous solution.
  • the active ingredient / active ingredient-containing particles are mixed with various auxiliary substances and either wet granulated / pressed or pressed directly.
  • Microcrystalline cellulose (MCC) eg Avicel
  • MCC Microcrystalline cellulose
  • effervescent mixture citric acid / sodium pumbicarbonate
  • the polymers used in Example 1 were used as viscosity-increasing and / or bioadhasive substances.
  • the disintegration was mainly influenced by the tablet hardness.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des préparations solides, à décomposition rapide, qui prolongent le temps de séjour dans la zone d'application, par exemple dans l'oeil.
PCT/DE1998/003739 1997-12-12 1998-12-11 Preparation a temps de sejour prolonge dans la zone d'application Ceased WO1999030683A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU24101/99A AU2410199A (en) 1997-12-12 1998-12-11 Preparation with a prolonged retention time at the site of application
EP98966561A EP1037606A1 (fr) 1997-12-12 1998-12-11 Preparation a temps de sejour prolonge dans la zone d'application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19756314.7 1997-12-12
DE1997156314 DE19756314C2 (de) 1997-12-12 1997-12-12 Zubereitung mit verlängerter Verweildauer am Applikationsort

Publications (1)

Publication Number Publication Date
WO1999030683A1 true WO1999030683A1 (fr) 1999-06-24

Family

ID=7852382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1998/003739 Ceased WO1999030683A1 (fr) 1997-12-12 1998-12-11 Preparation a temps de sejour prolonge dans la zone d'application

Country Status (4)

Country Link
EP (1) EP1037606A1 (fr)
AU (1) AU2410199A (fr)
DE (1) DE19756314C2 (fr)
WO (1) WO1999030683A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299621B1 (en) 1999-06-18 2001-10-09 Novare Surgical Systems, Inc. Surgical clamp pads with elastomer impregnated mesh
WO2009125432A3 (fr) * 2008-04-11 2010-03-25 Lupin Limited Systèmes d'administration de médicament expansible alimentés par gaz
CN109908328A (zh) * 2019-03-25 2019-06-21 华南理工大学 纳米透皮技术用于改善眼睛干眼症的眼贴及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19940795A1 (de) 1999-08-27 2001-03-01 Lohmann Therapie Syst Lts Schnellzerfallende Pellets auf der Basis von Chitosan

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2243986A1 (de) * 1971-09-09 1973-03-29 Alza Corp Biologisch abbaubarer augeneinsatz zur verabreichung eines arzneimittels
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
EP0251680A2 (fr) * 1986-06-25 1988-01-07 Iolab, Inc Système bioérodable pour la libération contrôlée d'un médicament
EP0451082A1 (fr) * 1990-04-03 1991-10-09 Laboratorios Cusi, S.A. Produit ophtalmique
DE4122591C1 (en) * 1991-07-08 1993-02-18 Roland 8012 Ottobrunn De Bodmeier Producing microcapsules of water insoluble polymer and active agent - includes dissolving or dispersing active agent in aq. polymer contg. gellable assistants
WO1994005257A1 (fr) * 1992-09-08 1994-03-17 Allergan, Inc. Liberation prolongee de medicaments ophtalmiques a partir d'un vehicule de diffusion de medicaments polymeres solubles
WO1996005810A1 (fr) * 1994-08-20 1996-02-29 Danbiosyst Uk Limited Composition d'apport de medicaments contenant du chitosane, ou un de ses derives, a potentiel zeta defini
WO1996027350A1 (fr) * 1995-03-07 1996-09-12 Sueverkruep Richard Forme galenique permettant d'administrer des produits et additifs pharmaceutiques, et leur procede de production
US5578567A (en) * 1990-09-20 1996-11-26 Sandoz Ltd. Nasal pharmaceutical composition
WO1996038174A1 (fr) * 1995-06-02 1996-12-05 Oculex Pharmaceuticals, Inc. Amelioration apportee a une formulation destinee a la liberation controlee de medicaments par combinaison d'agents hydrophiles et hydrophobes
WO1998056359A2 (fr) * 1997-06-13 1998-12-17 Roland Bodmeier Compositions retardant la liberation de principes actifs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222698A (en) * 1987-01-08 1990-02-26 Squibb & Sons Inc Bioadhesive suppository formulations comprising a medicament, water, a hydrocolloid and low melting point base
DE4139883A1 (de) * 1991-11-29 1993-06-03 Michael Prof Dr Dittgen Verfahren zur herstellung bioadhaesiver arzneimittel
FR2688694B1 (fr) * 1992-03-20 1999-06-25 Vetoquinol Sa Insert ophtalmique bioadhesif.

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
DE2243986A1 (de) * 1971-09-09 1973-03-29 Alza Corp Biologisch abbaubarer augeneinsatz zur verabreichung eines arzneimittels
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
EP0251680A2 (fr) * 1986-06-25 1988-01-07 Iolab, Inc Système bioérodable pour la libération contrôlée d'un médicament
EP0451082A1 (fr) * 1990-04-03 1991-10-09 Laboratorios Cusi, S.A. Produit ophtalmique
US5578567A (en) * 1990-09-20 1996-11-26 Sandoz Ltd. Nasal pharmaceutical composition
DE4122591C1 (en) * 1991-07-08 1993-02-18 Roland 8012 Ottobrunn De Bodmeier Producing microcapsules of water insoluble polymer and active agent - includes dissolving or dispersing active agent in aq. polymer contg. gellable assistants
WO1994005257A1 (fr) * 1992-09-08 1994-03-17 Allergan, Inc. Liberation prolongee de medicaments ophtalmiques a partir d'un vehicule de diffusion de medicaments polymeres solubles
WO1996005810A1 (fr) * 1994-08-20 1996-02-29 Danbiosyst Uk Limited Composition d'apport de medicaments contenant du chitosane, ou un de ses derives, a potentiel zeta defini
WO1996027350A1 (fr) * 1995-03-07 1996-09-12 Sueverkruep Richard Forme galenique permettant d'administrer des produits et additifs pharmaceutiques, et leur procede de production
WO1996038174A1 (fr) * 1995-06-02 1996-12-05 Oculex Pharmaceuticals, Inc. Amelioration apportee a une formulation destinee a la liberation controlee de medicaments par combinaison d'agents hydrophiles et hydrophobes
WO1998056359A2 (fr) * 1997-06-13 1998-12-17 Roland Bodmeier Compositions retardant la liberation de principes actifs

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299621B1 (en) 1999-06-18 2001-10-09 Novare Surgical Systems, Inc. Surgical clamp pads with elastomer impregnated mesh
WO2009125432A3 (fr) * 2008-04-11 2010-03-25 Lupin Limited Systèmes d'administration de médicament expansible alimentés par gaz
CN109908328A (zh) * 2019-03-25 2019-06-21 华南理工大学 纳米透皮技术用于改善眼睛干眼症的眼贴及其制备方法

Also Published As

Publication number Publication date
EP1037606A1 (fr) 2000-09-27
DE19756314C2 (de) 2000-06-29
DE19756314A1 (de) 1999-06-24
AU2410199A (en) 1999-07-05

Similar Documents

Publication Publication Date Title
EP0621777B1 (fr) Corps solides renfermant une matiere active, a structure composee de macromolecules hydrophiles, et leur procede de fabrication
DE69629797T2 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
DE69617245T2 (de) Produkte mit gesteuerter freisetzung
EP0918513B1 (fr) Medicament a administration orale facile a avaler
DE69524398T2 (de) Flüssige mittel zur wirkstoffabgabe
EP2164462B1 (fr) Préparation pharmaceutique pour produire des comprimés à délitement rapide
EP0650354B1 (fr) Solutions solides et liquides de substances medicamenteuses peu solubles dans l'eau
EP1545454A1 (fr) Forme d'administration solide a liberation rapide et destinee a une application orale de principes actifs a solubilite reduite
DE2908847B2 (de) Pharmazeutische Zubereitung mit verzögerter Freigabe
EP3634379B1 (fr) Pastille en mousse à décomposition rapide, présentant un poids surfacique élevé
DE4201179A1 (de) Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
DE69806236T2 (de) Verfahren zur herstellung fester pharmazeutischer dosisformen
DE19856432A1 (de) Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
EP2164461A1 (fr) Préparation pharmaceutique pour produire des comprimés à mâcher et à sucer
EP1029892A1 (fr) Agent séché par congélation contenant des polysaccharides et spécialement du paramylon, sa production et son utilisation
EP0615442B1 (fr) Matrice thermocollo dale reglee par des sols a base de gelatine utile dans des formes d'administration perorale a action prolongee
DE69119217T2 (de) Zusammensetzungen zur kontrollierten freigabe
EP1965761A2 (fr) Formulation pharmaceutique destinee a la fabrication de comprimes a desintegration rapide
EP2413910A1 (fr) Comprimés contenant de la dapoxétine et procédé de traitement à sec pour leur préparation
KR100258642B1 (ko) 신속하게 용해되는 경구 제형
Saettone et al. Controlled release of pilocarpine from coated polymeric ophthalmic inserts prepared by extrusion
JP4917738B2 (ja) 有効成分を目に投与するための固体ガレヌス製剤、固体で可溶性の目で用いるインサートおよび該インサートの製法
EP1178777A2 (fr) Forme galenique pour administration dans des orifices corporels
DE19756314C2 (de) Zubereitung mit verlängerter Verweildauer am Applikationsort
WO2012119997A1 (fr) Composition pharmaceutique pour la fabrication de comprimés à délitement rapide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998966561

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998966561

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998966561

Country of ref document: EP